Buscar
Forte Biosciences Inc
FBRXAñadir a la lista de seguimiento
76.600USD
-0.380-0.49%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.57BCap. mercado
PérdidaP/E TTM
Más Datos de Forte Biosciences Inc Compañía
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Información de Forte Biosciences Inc
Símbolo de cotizaciónFBRX
Nombre de la empresaForte Biosciences Inc
Fecha de salida a bolsaApr 13, 2017
Director ejecutivoWagner (Paul A)
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 13
Dirección3060 Pegasus Park Drive
CiudadDALLAS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal75247
Teléfono13106186994
Sitio Webhttps://www.fortebiorx.com/home/default.aspx
Símbolo de cotizaciónFBRX
Fecha de salida a bolsaApr 13, 2017
Director ejecutivoWagner (Paul A)
Ejecutivos de Forte Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
85.48K
+1.35%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
42.22K
+0.57%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
85.48K
+1.35%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
42.22K
+0.57%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Forte Biosciences Inc?
Los cinco principales accionistas de Forte Biosciences Inc son: Dr. Paul A. Wagner, Ph.D.
¿Cuántas instituciones poseen acciones de Forte Biosciences Inc (FBRX)?
A fecha de 2026Q1, 108 instituciones poseen acciones de Forte Biosciences Inc, con un valor de mercado combinado de aproximadamente 12.72M, lo que representa el 65.47% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 288877.00.